Publications by authors named "Yasufumi Nishii"
Importance: To date, several theta burst stimulation (TBS) protocols, such as intermittent TBS (iTBS), have been proposed; however, previous systematic reviews have revealed inconsistent efficacy findings in individual TBS studies for schizophrenia.
Objective: To examine which TBS protocols are associated with the most favorable and acceptable outcomes in adults with schizophrenia.
Data Sources: The Cochrane Library, PubMed, and Embase databases were searched for studies published before May 22, 2024.
Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression.
Pharmacopsychiatry
September 2024
Article Synopsis
- A study compared the effects of Lurasidone (LUR) and Quetiapine Extended Release (QUE-ER) on treatment discontinuation in patients with bipolar depression over one year, involving 317 participants.
- Although no significant difference in overall discontinuation rates was found between the two medications (p=0.317), adverse events (AEs) were linked to increased discontinuation risk (p<0.0001).
- The main AEs were akathisia for LUR and somnolence for QUE-ER, with each associated with higher discontinuation rates for their respective medications.
Article Synopsis
- A systematic review and meta-analysis were conducted to evaluate the effectiveness of serotonin 3 receptor antagonists (5-HT3R-As) in treating obsessive-compulsive disorder (OCD) by analyzing data from 10 double-blind, randomized, placebo-controlled trials involving 628 participants.
- * The analysis showed that 5-HT3R-As significantly improved the overall OCD symptoms (measured by the Yale-Brown Obsessive Compulsive Scale), including both obsession and compulsion scores when compared to placebo.
- * Despite these positive outcomes, there were no significant differences in treatment discontinuation or adverse event rates between 5-HT3R-As and placebo, indicating the need for further studies with larger sample sizes to confirm these findings